Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
This collaboration between Bristol Myers Squibb (BMS) and BioArctic signals a deeper commitment by BMS to tackling Alzheimer’s disease through innovative approaches. Here’s a breakdown of the key details:
Deal Overview:
- Upfront Payment: $100 million.
- Milestone Payments: Up to $1.25 billion, making the total deal potentially worth $1.35 billion.
- Royalties: BioArctic will receive tiered low double-digit royalties on future sales.
Target Programs:
- Pyroglutamate-Amyloid-Beta Antibodies:
- BAN1503 and BAN2803 target pyroglutamate-modified amyloid-beta, a toxic form of amyloid-beta linked to Alzheimer’s plaques.
- This represents a novel approach to targeting the protein believed to play a central role in Alzheimer’s progression.
- Brain Transporter Technology:
- BAN2803 incorporates BioArctic’s proprietary Brain Transporter technology.
- This innovation uses transferrin receptor proteins to cross the blood-brain barrier, offering advantages such as faster uptake, improved efficacy, lower side effects, and reduced dosing requirements.
Broader Implications:
- BioArctic’s Success: The deal marks BioArctic’s first licensing agreement featuring its Brain Transporter technology. News of the collaboration boosted BioArctic’s stock by ~30%.
- BMS’s Strategy:
- BMS continues to expand its neuroscience portfolio.
- The company recently acquired Karuna Therapeutics for $14 billion, adding KarXT, a drug now approved for schizophrenia and in trials for Alzheimer’s psychosis.
- This focus demonstrates BMS’s intent to address both the cognitive and psychotic symptoms of neurodegenerative diseases.
This partnership highlights a shift in Alzheimer’s R&D towards innovative mechanisms and precision delivery systems that could redefine treatment efficacy and patient outcomes.
